Global leaders at the G7 summit pledged 870 million COVID-19 vaccine doses, with half to be delivered by the end of 2021, to COVAX for distribution among low- and middle-income countries.
List view / Grid view
Coalition for Epidemic Preparedness Innovation (CEPI)
The first trial participant has been given INO-4500 in Ghana - INO-4500 is a DNA vaccine candidate being developed to protect against Lassa fever.
Through COVAX, doses of the Pfizer-BioNTech vaccine will be provided at a not-for-profit price for 92 low- and lower-middle-income countries.
The UK Government is supporting the development of COVID-19 vaccines, including two innovative UK vaccine candidates. In this article, we describe the history of these candidates and introduce innovative small and medium enterprises (SMEs) and national capabilities that are working to combat the current pandemic and improve the UK’s vaccine…
Contributing to ACT Accelerator could generate $466 billion for major economies, says Eurasia Group report
The report found that the 10 major economies could see a return of more than $466 billion by 2025, 12 times the total estimated cost of supporting the WHO’s Access to COVID-19 Tools (ACT) Accelerator.
Subject to regulatory approval, EU member states will be supplied with the potentially highly effective BNT162b2 COVID-19 vaccine candidate.